Toward Maximizing Immunotherapy in Metastatic Castration Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
Prostate cancer is particularly suited for active immunotherapy because of the expression of a distinctive number of antigens which are overexpressed on prostate cancer cells and cell lines. There is evidence in this disease that tumors promote immune tolerance starting early in the disease course....
Main Author: | Susan F Slovin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00043/full |
Similar Items
-
PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01) -
Aptamers as Theragnostic Tools in Prostate Cancer
by: Carlos David Cruz-Hernández, et al.
Published: (2022-07-01) -
Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
by: Govinda Nanjaiah Laxmana Raju, et al.
Published: (2023-06-01) -
<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01) -
Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)